|
(Health-NewsWire.Net, October 04, 2021 )
Market Overview
Allergy immunotherapy is a medical treatment for allergic reactions to allergens, including various foods, drugs, bee venom, grass pollens, and house dust mites. It alters the immune system’s response by gradually increasing the doses of the allergen.
View full report: https://bit.ly/3A7gifA
Market Dynamics
The increasing prevalence of allergic rhinitis is expected to drive the market's growth.
According to the Asthma and Allergy Foundation of America, allergic rhinitis (AR) is an IgE inflammatory response in the nasal mucosa following exposure to allergens that the subject is sensitized to symptoms mainly include rhino rhea and nasal congestion, sneezing, pruritus, and eye signs such as redness and itching/watery eyes. Besides physical discomfort, AR patients often present sleep disturbances, school absenteeism, impaired workability, and quality of life.
It affects 5.2 million of the children population and 19.2 million of the adult population. In addition, in 2018, white children were more likely to have hay fever than Black children, and the same triggers for indoor/outdoor allergies also often cause eye allergies. As per the Canadian Allergy, Asthma, and Immunology Foundation, allergic rhinitis affects nearly 20 to 25% of the Canadian population.
Complex allergies with high morbidity are a burden on the healthcare system, hence driving R&D in the allergy immunotherapies market for the launch of novel therapies. In addition, rising air pollution, both indoors and outdoors, has led to increasing in the prevalence of asthma and allergic disorders of the respiratory tract. According to the Asthma and Allergy Foundation of America (AAFA), more than 25 million allergies are caused due to increased pollen counts.
Thus, with rising in the demand for allergy immunotherapies, major companies are focused on the development of innovative immunotherapy products.
Segment Analysis
By Treatment Type
• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)
By Allergy Type
• Allergic rhinitis
• Allergic asthma
• Others
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Download free sample: https://bit.ly/3D5Yp2H
Geographical Analysis
Europe region holds the largest market share in the global allergy immunotherapies market
Europe dominated the market in 2020. The growth of allergy immunotherapies in Europe is benefited due to the increasing prevalence of allergic disorders, the strong presence of leading market players, and R&D for the development of effective and safer allergen-specific immunotherapy practices is expected to boost the market in the forecast period.
Allergen immunotherapy (AIT) is the only perspective in which a vaccine is applied to patients allergic to the active principle in the vaccine. More than 150 million Europeans suffer from allergic disorders and expected that more than 50% of the population in this region would be affected by at least one form of allergy by 2025 owing to various factors, such as industrialization, urbanization, climate change, and pollution.
Competitive Landscape
The allergy immunotherapies market is highly competitive with the presence of several players in the market. Some of the key players which are contributing to the growth of the market include Merck KGaA, Stallergenes Greer plc, Allergy Therapeutics, Mylan N.V., ASIT Biotech, DVB Technologies SA, LETIPharma.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the allergy immunotherapies market globally. For instance, in October 2019, Stallergenes Greer Ltd. collaborated with Anergis, a Switzerland-based clinical-stage biopharma company, to initiate a research study focused on the evaluation of the second-generation contiguous overlapping peptides allergen immunotherapy for birch pollen allergy.
Related Topic's
Cancer Immunotherapy Market, Immunotherapy Drugs Market, Allergy Treatment Market, Narcolepsy Therapeutics Market, Acne Therapeutics Market
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
